摘要
FMS样酪氨酸激酶3基因内部串联重复序列（FLT3-ITD）突变是急性髓系白血病（AML）中常见的突变类型,其突变与AML的发生、发展及不良预后关系密切.FLT3-ITD突变阳性AML患者常规化学治疗预后差,复发率高,异基因造血干细胞移植对该类患者疗效不一,索拉非尼等靶向治疗及不同治疗方式的联合治疗的临床前及临床试验已经开展且已初见成效.文章就FLT3-ITD突变在AML中的临床意义及对该类患者治疗的最新进展作一综述.
FMS-like tyrosine kinase 3 internal tandem duplication （FLT3-ITD） mutation is a commonly found type of mutation in acute myeloid leukemia （AML）, and this mutation is closely related to the development of AML and affects the prognosis of patients. FLT3-ITD-positive AML patients have poor prognosis and high relapse rate after treated with chemotherapy alone. The efficacy of allogeneic hematopoietic stem cell transplantation for this disease is controversial. Targeted therapies such as sorafenib and the combination of different type of therapies have been carried out and have shown preliminary effect in preclinical or clinical trials. In this paper, the clinical effect of FLT3-ITD in AML patients and the latest progress of its treatment were reviewed.
作者
郭丽萍
侯丽虹
Guo Liping;Hou Lihong(Graduate School,Shanxi Medical University,Taiyuan 030001,China;Department of Hematology,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处
《白血病．淋巴瘤》
CAS
2018年第6期379-384,共6页
Journal of Leukemia & Lymphoma
基金
山西省回国留学人员科研资助项目（2015-102）
